Současné možnosti léčby nivolumabem u nemocných s klasickým Hodgkinovým lymfomem
| Title in English | Current therapy options with nivolumab in patients with classic Hodgkin lymphoma |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Onkol Revue |
| Citation | |
| Description | Nivolumab therapy should be currently a first choice for patients with classic Hodgkin lymphoma relapsed after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Because of specific immune mechanism of action with no direct cytotoxicity on tumor cells, favorable toxicity profile and declared efficacy even in otherwise refractory cases there is an effort to use it in more therapy settings. In this review we mention different clinical situations and possibilities of therapeutic potential of nivolumab with references on clinical trials results. |